Allergy Therapeutics - Board Appointment

Allergy Therapeutics - Board Appointment

2 May 2012
Allergy Therapeutics plc
 
("Allergy Therapeutics" or the "Company")
Appointment of a Non-Executive Director
Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has appointed with immediate effect Dr. Thomas Lander, as a Non-Executive Director with European regulatory experience.
Dr Thomas Lander will replace Dr Virinder Nohria, and will be responsible for overseeing the Company's research and development activities. Dr Nohria retires from the Board on 30 June 2012, as Non-Executive Director.

Thomas has more than 25 years experience in the biopharmaceutical industry. He has held a number of senior management positions with international pharmaceutical companies including Boehringer Ingelheim, NovoNordisk and Bristol-Myers Squibb. Thomas was European Medical Director of GlaxoWellcome until the merger that resulted in GlaxoSmithKline (Other OTC: GLAXF.PK - news) before he became Global Head of Clinical Development and Chief Medical Officer of Merck KGaA (now MerckSerono). He was appointed Managing Director of CureVac GmbH in 2006. Since 2009 he has been working as an independent strategic consultant.

Peter Jensen Chairman of Allergy Therapeutics commented:


"We are delighted to welcome Thomas to the Board. He brings extensive industry and board experience, which will be invaluable to the Company as it continues to execute its global R∓D strategy."


Additional information regarding Thomas Lander

Thomas Lander aged 59 has the following appointments as a director or partner within the past 5 years:
 

Current
 

Lander Goette Biopharma Consulting GbR

Former (past 5 years)
 

Lipid Therapeutics GmbH
 
CT Atlantic AG

Vasopharm GmbH
 

 

There are no further disclosures required under Schedule 2 paragraph (g) of the AIM rules.
 

 


For further information
 

 

 

.Allergy Therapeutics.
 

.+44 (0) 1903 845 820.
 

 

Manuel Llobet, Chief Executive Officer
 

 

Ian Postlethwaite, Finance Director
 

www.allergytherapeutics.com
 

 

 

.Nomura Code Securities.
 

.+44 (0) 207 776 1200.
 

 

Juliet Thompson/ Clare Terlouw
 

 

 

 

 

 

 

 

 

.FTI Consulting (NYSE: FCN - news) .
 

.+44 (0) 207 831 3113.
 

 

Jonathan Birt/ Susan Quigley/ Simon Conway
 

 

 

 

 

Notes to editors
 


About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe (Chicago Options: ^REURUSD - news) through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.